• Explore /
  • Poster
  • / <em>HSD3B1</em> (1245A>C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (AA) and enzalutamide (ENZA): Results from two prospective studies.

HSD3B1 (1245A>C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (AA) and enzalutamide (ENZA): Results from two prospective studies.

Abstract Video & Slides Poster

Authors

null

Isabel Aragon

Genitourinary Cancer Traslational Research Unit, Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain

Isabel Aragon , Daniel Joseph Khalaf , Rebeca Lozano , Matti Annala , Sinja Taavitsainen , David Lorente , Daygen L. Finch , Nuria Romero-Laorden , Joanna Vergidis , Ylenia Cendon , Conrad D. Oja , Maria I Pacheco , Muhammad Zulfiqar , Martin Gleave , Alexander William Wyatt , David Olmos , Elena Castro , Kim N. Chi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5525)

DOI

10.1200/JCO.2020.38.15_suppl.5525

Abstract #

5525

Poster Bd #

106

Abstract Disclosures

Similar Posters

First Author: Esmail M. Al-Ezzi

First Author: Tilman Todenhöfer

First Author: Evan Y. Yu

First Author: Louise Emmett